dr. moore on unanswered questions with parp inhibitors in ovarian cancer
Published 4 years ago • 208 plays • Length 2:23Download video MP4
Download video MP3
Similar videos
-
2:03
dr. moore on treatment for patients with ovarian cancer who develop resistance to parp inhibitors
-
2:25
dr. naumann on unanswered questions with parp inhibitors in ovarian cancer
-
2:32
dr. moore on research evaluating repeat exposure to parp inhibition in ovarian cancer
-
1:40
dr. moore on immunotherapy and parp combinations in brca-mutated ovarian cancer
-
2:09
dr. moore on the nova trial for ovarian cancer
-
21:52
esmo 2018: dr. moore speaks to exciting parp inhibitor abstracts in ovarian cancer
-
1:34
dr. moore on challenges with immunotherapy in ovarian cancer
-
1:41
dr. moore on benefit of mirvetuximab soravtansine in patients with ovarian cancer
-
1:50
dr. moore on results of the forward i/gog 3011 trial in ovarian cancer
-
1:16
dr. moore discusses combinations in ovarian cancer
-
2:15
dr. moore on early-phase data with mirvetuximab soravtansine in ovarian cancer
-
0:54
dr. moore on the prevalence of ovarian cancer
-
1:49
dr. moore on safety profile of mirvetuximab soravtansine in ovarian cancer
-
2:28
dr. moore on the role of mirvetuximab soravtansine in ovarian cancer
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
5:28
ongoing parp inhibitor research in ovarian cancer
-
5:34
differences among parp inhibitors in ovarian cancer
-
6:25
combinations with parp inhibitors for ovarian cancer
-
2:43
dr. moore on the impact of solo-1 in ovarian cancer